Compounds and methods for treating pain

Patent metadata

Field	Value
Publication number	US-10899796-B2
Application number	US-201615774451-A
Country	US
Kind code	B2
Filing date	Nov 9, 2016
Priority date	Nov 9, 2015
Publication date	Jan 26, 2021
Grant date	Jan 26, 2021

Abstract

The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.

First claim

What is claimed is:

1. A composition comprising a bovine adrenal medulla peptide 8-22 (BAM8-22) peptide comprising a PEG-8 linker with a KGG spacer, and a palmitic acid membrane anchor, wherein:
the BAM8-22 peptide comprises the amino acid sequence of SEQ ID NO: 1; or
the BAM8-22 peptide comprises an amino acid modification selected from a M to A substitution at position 15 of SEQ ID NO: 1 (M15A), and a Y to W substitution at position 17 of SEQ ID NO: 1 (Y17W); and
the PEG-8 linker and the palmitic acid membrane anchor are coupled to the amino side chain group of the C-terminal lysine in the KGG spacer of the BAM8-22 peptide.

2. The composition of claim 1 , wherein the BAM8-22 peptide and the KGG spacer comprise the amino acid sequence of SEQ ID NO: 2.

3. The composition of claim 1 , having the following structure:

4. The composition of claim 1 , wherein the BAM8-22 peptide comprises M15A and Y17W amino acid modifications.

5. A pharmaceutical composition comprising a composition of claim 1 and a pharmaceutically acceptable carrier.

6. A method of treating neuropathic pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

7. The method of claim 6 , wherein the subject is a mammal.

8. A method of treating ocular pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

9. The method of claim 8 , wherein the subject is a mammal.

10. A method of treating ocular inflammation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

11. The method of claim 10 , wherein the subject is a mammal.

12. A method of treating dry eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition of claim 1 .

13. The method of claim 12 , wherein the subject is a mammal.

Assignees

• Tufts Medical Center
• Tufts College

Inventors

• Kopin Alan S
• Kumar Krishna
• Doyle Jamie Raudensky

Classifications

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/33

  derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin · CPC title

• C07K7/00

  Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof · CPC title

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• C07K7/64

  Cyclic peptides containing only normal peptide links · CPC title